CTGLF2 Inhibitors
CTGLF2 inhibitors represent a class of chemical compounds specifically designed to target and impede the action of the CTGLF2 protein. The CTGLF2 protein is involved in a range of cellular processes, and the inhibitors function by binding to the active site or an allosteric site of this protein, thereby obstructing its activity. These inhibitors are characterized by their selective affinity for the CTGLF2 protein, allowing them to effectively block the protein's function without affecting other proteins with similar structures or functions. This specificity is achieved through molecular design that takes advantage of the unique three-dimensional structure of CTGLF2, including its active or allosteric sites, where the inhibitors fit like a key in a lock. By binding to these sites, CTGLF2 inhibitors can prevent the protein from interacting with its natural substrates or partners, thus halting any downstream signaling or metabolic pathways that the protein normally influences.
The mechanism of action of CTGLF2 inhibitors is grounded in their ability to disrupt the biochemical pathways that the CTGLF2 protein regulates. These pathways could include signal transduction mechanisms, gene expression regulation, or any other cellular process in which the CTGLF2 protein plays a pivotal role. By obstructing these pathways, CTGLF2 inhibitors lead to a decrease in the functional activity of the protein. It's worth noting that these inhibitors are not merely antagonists that block protein function, but rather they act to impede the protein's activity by causing conformational changes or by sterically hindering the protein from executing its normal biological process. The design and development of CTGLF2 inhibitors are driven by a deep understanding of the protein's structure and the molecular dynamics that govern its function. This knowledge enables the creation of inhibitors that are both potent and precise in their action, effectively silencing the activity of CTGLF2 without interfering with other cellular components.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. CTGLF2, if involved in PI3K/AKT signaling, would be inhibited as PI3K activity is critical for AKT activation, which could lead to downstream effects on cellular survival and growth. By inhibiting PI3K, wortmannin can prevent the phosphorylation and activation of AKT, indirectly leading to the inhibition of CTGLF2 if it is downstream of this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin, and it acts by blocking the ATP binding site of PI3K. If CTGLF2 functions downstream of PI3K/AKT pathway, LY294002 would lead to decreased activation of AKT, potentially reducing CTGLF2 activity if it is regulated by AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is a downstream effector of PI3K/AKT pathway. Inhibition of mTOR can lead to decreased protein synthesis and cell proliferation, which might indirectly reduce CTGLF2 activity if it is involved in these processes. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor, which acts by preventing AKT phosphorylation and activation. If CTGLF2 is an AKT substrate or is regulated by AKT-dependent signaling, triciribine would result in its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. If CTGLF2 is involved in the MAPK pathway or is regulated by ERK signaling, inhibition of MEK by U0126 would prevent ERK activation, thereby potentially inhibiting CTGLF2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that works similarly to U0126. It blocks the activation of MEK, which in turn would prevent the activation of ERK. If CTGLF2 is linked to the MAPK pathway, PD98059 could indirectly inhibit CTGLF2 by preventing ERK-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. If CTGLF2 is a part of the p38 MAPK stress response pathway, SB203580 would hinder its activation and therefore inhibit any CTGLF2 activity that is p38-dependent. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress signaling and apoptosis. If CTGLF2 functions are regulated by JNK signaling, inhibition by SP600125 would lead to a decrease in CTGLF2 activity. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, which is essential for pyrimidine synthesis, a requirement for DNA synthesis and cell proliferation. If CTGLF2 activity is linked to cell cycle progression, leflunomide could result in an indirect inhibition of CTGLF2 by limiting cell proliferation. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide modulates the degradation of transcription factors, notably by promoting the degradation of SALL4, a protein implicated in stem cell pluripotency. If CTGLF2 is regulated by factors that are degraded by thalidomide action, this could lead to an indirect inhibition of CTGLF2 function. | ||||||